Clinical Trial Update: A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70) [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of vupanorsen (TRANSLATE-TIMI 70) has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Hyperlipidemias

Drugs mentioned

• Vupanorsen (null)

Snippet

Sponsor: Pfizer | Conditions: Dyslipidemias, Hyperlipidemias | Phase 2 | Status: COMPLETED | Results posted: 2022-10-04